Titre : Vibrio

Vibrio : Questions médicales fréquentes

Termes MeSH sélectionnés :

Fumarates
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vibrio : Questions médicales les plus fréquentes", "headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-05", "dateModified": "2025-04-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vibrio" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vibrionaceae", "url": "https://questionsmedicales.fr/mesh/D014737", "about": { "@type": "MedicalCondition", "name": "Vibrionaceae", "code": { "@type": "MedicalCode", "code": "D014737", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio alginolyticus", "alternateName": "Vibrio alginolyticus", "url": "https://questionsmedicales.fr/mesh/D044149", "about": { "@type": "MedicalCondition", "name": "Vibrio alginolyticus", "code": { "@type": "MedicalCode", "code": "D044149", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.030" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae", "alternateName": "Vibrio cholerae", "url": "https://questionsmedicales.fr/mesh/D014734", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae", "code": { "@type": "MedicalCode", "code": "D014734", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio cholerae non-O1", "alternateName": "Vibrio cholerae non-O1", "url": "https://questionsmedicales.fr/mesh/D044163", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae non-O1", "code": { "@type": "MedicalCode", "code": "D044163", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.075" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O1", "alternateName": "Vibrio cholerae O1", "url": "https://questionsmedicales.fr/mesh/D041241", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O1", "code": { "@type": "MedicalCode", "code": "D041241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.151" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O139", "alternateName": "Vibrio cholerae O139", "url": "https://questionsmedicales.fr/mesh/D041242", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O139", "code": { "@type": "MedicalCode", "code": "D041242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Vibrio mimicus", "alternateName": "Vibrio mimicus", "url": "https://questionsmedicales.fr/mesh/D044164", "about": { "@type": "MedicalCondition", "name": "Vibrio mimicus", "code": { "@type": "MedicalCode", "code": "D044164", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.500" } } }, { "@type": "MedicalWebPage", "name": "Vibrio parahaemolyticus", "alternateName": "Vibrio parahaemolyticus", "url": "https://questionsmedicales.fr/mesh/D014736", "about": { "@type": "MedicalCondition", "name": "Vibrio parahaemolyticus", "code": { "@type": "MedicalCode", "code": "D014736", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.590" } } }, { "@type": "MedicalWebPage", "name": "Vibrio vulnificus", "alternateName": "Vibrio vulnificus", "url": "https://questionsmedicales.fr/mesh/D041261", "about": { "@type": "MedicalCondition", "name": "Vibrio vulnificus", "code": { "@type": "MedicalCode", "code": "D041261", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Vibrio", "alternateName": "Vibrio", "code": { "@type": "MedicalCode", "code": "D014733", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jaime Martinez-Urtaza", "url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza", "affiliation": { "@type": "Organization", "name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain." } }, { "@type": "Person", "name": "Jessica L Jones", "url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones", "affiliation": { "@type": "Organization", "name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136." } }, { "@type": "Person", "name": "William C Walton", "url": "https://questionsmedicales.fr/author/William%20C%20Walton", "affiliation": { "@type": "Organization", "name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA." } }, { "@type": "Person", "name": "Julia C van Kessel", "url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel", "affiliation": { "@type": "Organization", "name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu." } }, { "@type": "Person", "name": "Blake Ushijima", "url": "https://questionsmedicales.fr/author/Blake%20Ushijima", "affiliation": { "@type": "Organization", "name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes.", "datePublished": "2022-06-14", "url": "https://questionsmedicales.fr/article/35747720", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/6935758" } }, { "@type": "ScholarlyArticle", "name": "Characterization of stress degradation products of bedaquiline fumarate and bedaquiline by LC-PDA and LC-MS.", "datePublished": "2023-08-18", "url": "https://questionsmedicales.fr/article/37619292", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jpba.2023.115658" } }, { "@type": "ScholarlyArticle", "name": "Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.", "datePublished": "2023-09-05", "url": "https://questionsmedicales.fr/article/37695583", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2023.32968" } }, { "@type": "ScholarlyArticle", "name": "Preparation of pazopanib-fumarate disodium glycyrrhizinate nanocrystalline micelles by liquid-assisted ball milling.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37459902", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejps.2023.106530" } }, { "@type": "ScholarlyArticle", "name": "Very low monomethyl fumarate exposure via human milk: a case report-a contribution from the ConcePTION project.", "datePublished": "2024-07-02", "url": "https://questionsmedicales.fr/article/39015385", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2024.1393752" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Bactéries", "item": "https://questionsmedicales.fr/mesh/D001419" }, { "@type": "ListItem", "position": 3, "name": "Proteobacteria", "item": "https://questionsmedicales.fr/mesh/D020560" }, { "@type": "ListItem", "position": 4, "name": "Gammaproteobacteria", "item": "https://questionsmedicales.fr/mesh/D020563" }, { "@type": "ListItem", "position": 5, "name": "Vibrionaceae", "item": "https://questionsmedicales.fr/mesh/D014737" }, { "@type": "ListItem", "position": 6, "name": "Vibrio", "item": "https://questionsmedicales.fr/mesh/D014733" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vibrio - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vibrio", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vibrio", "description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Fumarates&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vibrio", "description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Fumarates&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vibrio", "description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Fumarates&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vibrio", "description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Fumarates&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vibrio", "description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Fumarates&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vibrio", "description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Fumarates&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection à Vibrio ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Vibrio ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés." } }, { "@type": "Question", "name": "Les tests sérologiques sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio." } }, { "@type": "Question", "name": "Peut-on diagnostiquer Vibrio par PCR ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons." } }, { "@type": "Question", "name": "Quels symptômes orientent vers un diagnostic de Vibrio ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection à Vibrio ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre." } }, { "@type": "Question", "name": "La diarrhée est-elle toujours présente ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio." } }, { "@type": "Question", "name": "Les infections à Vibrio causent-elles de la fièvre ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas." } }, { "@type": "Question", "name": "Y a-t-il des symptômes graves associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils rapidement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection." } }, { "@type": "Question", "name": "Comment prévenir les infections à Vibrio ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains." } }, { "@type": "Question", "name": "Le lavage des mains est-il important ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes." } }, { "@type": "Question", "name": "Les vaccinations existent-elles contre Vibrio ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio." } }, { "@type": "Question", "name": "Faut-il éviter certains aliments ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies." } }, { "@type": "Question", "name": "Les voyages augmentent-ils le risque d'infection ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection." } }, { "@type": "Question", "name": "Quel est le traitement principal pour Vibrio ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire." } }, { "@type": "Question", "name": "Quels antibiotiques sont efficaces contre Vibrio ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés." } }, { "@type": "Question", "name": "La réhydratation est-elle toujours nécessaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère." } }, { "@type": "Question", "name": "Les traitements sont-ils différents selon le type de Vibrio ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection." } }, { "@type": "Question", "name": "Les probiotiques aident-ils dans le traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Vibrio ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale." } }, { "@type": "Question", "name": "La déshydratation est-elle une complication fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère." } }, { "@type": "Question", "name": "Les infections à Vibrio peuvent-elles être mortelles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide." } }, { "@type": "Question", "name": "Y a-t-il des risques pour les personnes immunodéprimées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves." } }, { "@type": "Question", "name": "Les infections cutanées sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour Vibrio ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio." } }, { "@type": "Question", "name": "Le diabète augmente-t-il le risque d'infection ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio." } }, { "@type": "Question", "name": "Les personnes vivant près de l'eau sont-elles plus exposées ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été." } }, { "@type": "Question", "name": "Les voyages dans des zones endémiques sont-ils risqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection." } } ] } ] }

Sources (522 au total)

Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.

Pre-exposure prophylaxis (PrEP) is an important tool for preventing HIV infection. However, PrEP's impact on cardiometabolic health is understudied.... To examine the risk of incident hypertension and statin initiation among adult (age ≥18 years) health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared with propensity scor... This retrospective cohort study used electronic health records (EHRs) from Kaiser Permanente Southern California. Adult members starting PrEP in Kaiser Permanente Southern California between October 2... PrEP initiation with either TAF or TDF during the study period.... Incident hypertension and statin initiation within 2 years of PrEP initiation were ascertained through blood pressure and outpatient pharmacy records, respectively. Risk differences and odds ratios (O... A total of 6824 eligible individuals were identified (mean [SD] age, 33.9 [10.3] years; 6618 [97%] male). This pool was used to generate 2 cohorts without baseline hypertension or statin use for match... In this study of people taking PrEP, TAF use was found to be associated with higher incident hypertension and statin initiation compared with TDF use, especially in those 40 years or older. Continued ...

Very low monomethyl fumarate exposure via human milk: a case report-a contribution from the ConcePTION project.

While breastfeeding is recommended, knowledge regarding medicine transfer to human milk and its safety for nursing infants is limited. Only one paper has previously described dimethyl fumarate (DMF) t... A 32-year-old Caucasian woman started DMF therapy (120 mg, 2x/day) for multiple sclerosis at 3 months postpartum, after weaning her infant from breastfeeding. On day 99 after birth, the patient collec... A wide range of measured steady-state concentrations of MMF (5.5-83.5 ng/mL) was observed in human milk samples. Estimated daily infant dosage values for MMF, calculated with 150 and 200 mL/kg/day hum... Combining this case report with the two previously described cases, the estimated infant exposure is low, albeit with relevant intra- and inter-patient variabilities. Research should further focus on ...

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.

Tenofovir disoproxil (TD), modified from tenofovir disoproxil fumarate (TDF), was developed as a salt-free formulation, removing fumarate to improve the ease of oral intake by reducing the tablet's si... CHB patients with HBV-DNA <69 IU/mL after ≥24 weeks of TDF therapy were enrolled. The primary efficacy endpoint was the HBV-DNA suppression rate (HBV-DNA <69 IU/mL) at week 48; We evaluated the non-in... Overall, 189 subjects were randomized in a 2:1 ratio, and 117 and 66 subjects in the TD and TDF groups, respectively, completed the study. In the per-protocol set, the HBV-DNA suppression rate at week... TD was non-inferior to TDF for maintaining viral suppression in CHB patients, showing the less decline of renal function....